What is the Prognosis for T790M-Positive Patients?
The prognosis for T790M-positive patients has improved with the advent of third-generation TKIs. Studies have shown that osimertinib provides a median progression-free survival of around 10 months in this patient population. Additionally, the overall survival rates have also improved, offering hope for better long-term outcomes.
